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Abstract
The “complement system” is one of the effector pathways of the immune system against 
microorganisms and tumor cells. The complement system can be activated through three 
major pathways: classical, lectin, and alternative. The sequential activation through the 
generation of complex enzymes from inactive zymogens produces a cascade in which a 
capable enzyme generates a large number of active downstream molecules.
C1 inhibitor (C1‐INH) is a serine protease inhibitor (serpin) that regulates the  following 
closely interrelated proteolytic pathways: complement system, coagulation system, 
 contact system, and fibrinolysis system. The absence or malfunction of C1‐INH results 
in the presence of attacks of angioedema (AE) due to uncontrolled activation of the con‐
tact system, with the generation of bradykinin (BK), a vasoactive peptide released from 
high‐molecular‐weight kininogen (HMWK). Some drugs that inhibit the catabolism of BK 
have been implicated in the development of AE. These include angiotensin‐ converting 
enzyme inhibitors (ACEIs), dipeptidyl peptidase IV (DPP‐IV) inhibitors, aminopeptidase 
P (APP) inhibitors, and neutral endopeptidase (NEP) inhibitors.
We describe in this chapter the biochemistry pathways implicated in the pathophysiology 
of bradykininergic angioedema (BK‐AE) and the role of the complement system in the 
prototype of BK‐AE, in hereditary angioedema with C1‐INH deficiency (C1‐INH‐HAE), 
and also in acquired angioedema with C1‐INH deficiency (C1‐INH‐AAE).
Keywords: acquired angioedema, aminopeptidase P, angioedema, angiotensin‐
converting enzyme, bradykinin, C1 inhibitor, carboxypeptidase, complement system, 
contact system, dipeptidyl peptidase‐IV, endothelin‐converting enzyme‐1, factor XII, 
fibrinolysis system, hereditary angioedema, neutral endopeptidase
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1. Introduction: definition of angioedema and differentiation between 
histaminergic and bradykininergic angioedema
The term “angioedema” (AE) is defined as localized and transient subcutaneous and/or 
submucosal swelling (which may affect the gastrointestinal, respiratory, or genitourinary 
tract) [1, 2]. It occurs when there is vasodilation with consequent increase in capillary 
 permeability and extravasation of fluid into the interstitial space [2, 3].
A variety of inflammatory mediators have been described that can lead to this process, such 
as histamine, prostaglandins, leukotrienes, and bradykinin [4]. The most frequent type of 
AE is produced by histamine release, as a consequence of mast cell activation, and is called 
“histaminergic angioedema.”
It includes allergic reactions, but also idiopathic AE in the context of chronic spontaneous 
 urticaria [5]. Histaminergic AE can be associated to urticaria [6], is usually erythematous, 
warm, and pruritic, and is responsive to treatment with antihistamines [7]. The clinical 
expression of urticarial lesions is mainly a consequence of inflammation and edema of the 
upper dermis, whereas swellings are located in the deep dermis and even in the subcutane‐
ous tissue.
Another important type of AE is produced by an increase in bradykinin (BK). This AE type 
is non‐erythematous, non‐pruritic, cold, non‐responsive to antihistamines and urticaria is not 
associated [7]. This subgroup is known as bradykininergic angioedema (BK‐AE).
2. Classification of bradykinin‐mediated angioedema (BK‐AE)
BK‐AE comprises several entities (Table 1). In recent years, there has been a dramatic increase 
in knowledge about this condition, particularly on the role of BK as the “final common 
 mediator.” The Spanish Study Group for Angioedema due to C1‐inhibitor deficiency was 
established in 2007 within the Committee of Immunology of the Spanish Society of Allergology 
and Clinical Immunology (SEAIC). However, such was the progress in the understanding of 
the  pathophysiology of different types of BK‐AE that this group's name quickly changed to 
“Spanish Study Group on Bradykinin‐Induced Angioedema” (SGBA).
BK‐AE is mainly classified into two subtypes depending on whether or not there is a 
 functional deficiency of C1 esterase inhibitor, better known as C1 inhibitor (C1‐INH) (Table 1) 
[8]. Another common way to classify BK‐AE is hereditary angioedema (HAE) and acquired 
angioedema (AAE) [8]. There are two forms of AE with C1‐INH deficiency, a hereditary form 
(C1‐INH‐HAE) and an acquired form (C1‐INH‐AAE).
Among the forms of AE with no functionally active C1‐INH deficiency are hereditary angio‐
edema with normal C1‐INH (nC1‐INH‐HAE), with/without mutation in the F12 gene that 
encodes coagulation factor XII (FXII‐HAE/U‐HAE) or acquired AE associated with drugs 
that inhibit the metabolic pathways of BK, angiotensin‐converting enzyme inhibitors 
(ACEi‐AAE).
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Other drugs that inhibit the catabolism of BK have been implicated in the development of AE. 
These include dipeptidyl peptidase IV (DPP‐IV) inhibitors, aminopeptidase P (APP) inhibi‐
tors, neutral endopeptidase (NEP) inhibitors, and others.
Along with progress in biochemical‐molecular knowledge, much has been learned about the dif‐
ferent pathophysiological mechanisms of the different types of AE. For example, the initial term 
“HAE type III or oestrogen‐induced” has evolved into the term FXII‐HAE due to the description 
in some of these patients of mutations in the F12 gene. Another example would be the  recognition 
of antihypertensives belonging to the group of ACE inhibitors (ACEIs) as producers of AE by 
increased BK, secondary to the inhibition of its catabolism. This has led to classifications over time 
by different groups. In order to agree on a common name for all types of AE “without  papules” 
described so far, the HAE International Working Group (HAWK), under the sponsorship of the 
European Academy of Allergy and Clinical Immunology (EAACI), proposed a classification of 
AE without wheals as seen in Figure 1 [7], with four types of AAE and three types of HAE.
Bradykinin (BK)‐mediated 
angioedema (AE)
With verified C1‐inhibitor 
protein deficiency
Hereditary 
(C1‐INH‐HAE)
Type I (C1‐INH‐HAE type I)
Type II (C1‐INH‐HAE type II)
Acquired (C1‐INH‐AAE)
No verified C1 inhibitor 
protein deficiency
Hereditary (related to 
estrogen) (HAE type III)
With known mutation of F12 
gene (FXII‐HAE)
Without known mutation of F12 
gene (U‐HAE: HAE unknown)
Acquired associated with angiotensin‐converting enzyme 
(ACE) inhibitors (ACEis) (AAE‐ACEi)
Table 1. Classification of different types of bradykinin‐mediated AE (modified from SGBA Consensus) [9].
Figure 1. Classification of angioedema without wheals [7].
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However, this classification has some limitations such as the noninclusion of AE caused by 
non‐steroidal anti‐inflammatory drugs (NSAIDs), which often occurs without associated 
urticaria [10]. These drugs act by inhibiting the enzyme cyclooxygenase in the metabolic 
pathways of arachidonic acid and increasing leukotrienes.
A classification of AE according to endotypes was proposed later [11]. In this classification, three 
subtypes of AE were included: (1) mast cell and basophil‐driven AE, (2) bradykininergic AE, 
and (3) idiopathic AE [11]. It has the advantage that NSAIDs induced or exacerbated AE and 
allergic AE are both included within the mast cell and basophil‐driven AE.
3. C1‐inhibitor deficiency
C1‐INH is a serine protease inhibitor (serpin) that regulates the following closely 
 interrelated proteolytic pathways: complement system, coagulation system, contact system, 
and  fibrinolysis system [12, 13] (Figure 2). It is also known as SERPING1, belongs to the 
SERPIN superfamily, and is mainly synthesized in hepatocytes [9].
First, C1‐INH inhibits C1r, C1s, and mannose‐binding‐lectin‐associated serine proteases (MASP1, 
MASP2) in the complement system. The inhibition of C1r and C1s is the function that gives name 
to this protein, “C1 inhibitor.” The C1 fraction of complement, also known as C1 esterase, is the 
first protein of the complement system, and circulates in an inactive form. C1 esterase is activated 
during immunological processes, initiating the complement cascade and splitting off proteins 
from the classical pathway (C4 and C2) [9]. In patients with C1‐INH deficiency, an increase in C1 
esterase functioning produces decreased C2, C4 levels, the natural substrates of the complement 
C1s fraction, which diminish much more during AE attacks [9]. C3, the protein that follows C2 
in the classical complement cascade, is usually normal in patients with C1‐INH‐HAE, since it is 
not controlled by C1‐INH [9].
Figure 2. C1‐INH regulates different pathways: (A) complement system, (B) contact system, and (C) fibrinolysis system.
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Besides, C1‐INH inhibits factor XI and thrombin in the coagulation system and tissue plas‐
minogen activator and plasmin in the fibrinolytic system [9].
Finally, C1‐INH also inhibits factor XII and kallikrein in the contact system, being the main 
inhibitor of the contact system and of BK formation [9]. This is the crucial action involved in 
AE development when C1‐INH is lacking.
C1‐INH deficiency can produce an activation of the four described cascades, with a final 
increase in BK. BK produces vascular  hyperpermeability and edema formation [9].
C1‐INH is the most potent inhibitor of the contact system and thus low C1‐INH function can 
activate this system, with uncontrolled activation of FXII and increased formation of kallikrein. 
Kallikrein releases BK from high‐molecular‐weight kininogen (HMWK). The lack of C1‐INH 
also produces an increase in plasmin through the activation of the fibrinolytic system. The split 
of BK from HMWK induced by kallikrein is facilitated by the presence of plasmin [9].
C1‐INH is a glycoprotein with 478 amino acids. It is heavily glycosylated (approximately 
30% by weight). Its apparent molecular weight on sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS‐PAGE) is 104 kilodalton (kDa), but its calculated molecular weight 
is 76 kDa. It is formed by an N‐terminal domain of 113 amino acids and a serpin domain of 
365 amino acids [14].
The genetic study of SERPING1 gene, which codes C1‐INH, has identified more than 300 
 different mutations causing C1‐INH‐HAE [7].
There are classically two main types of AE due to C1‐INH deficiency: hereditary ( C1‐ INH‐HAE) 
and acquired (C1‐INH‐AAE). In turn, two types of C1‐INH‐HAE [9] have been described; in 
patients with type I (85%) there is decreased antigenic C1‐INH (consequently resulting in 
decreased functional activity); type II (15%) is characterized by normal C1‐INH levels with 
decreased functional C1‐INH (the molecule being dysfunctional) [9]. The acquired subtype is 
characterized by low levels of either antigenic and/or functional C1‐INH, associated in most 
cases with B‐cell lymphoproliferative disorders.
Hereditary or acquired deficiency of C1‐INH is characterized by recurrent episodes of circum‐
scribed, non‐itchy AE in submucosal or subcutaneous locations. AE attacks can be triggered 
by estrogens, trauma, infection, or stress.
4. What is the complement system?
The “Complement System” is one of the effector pathways of the immune system against 
microorganisms and tumor cells, consisting of about 30 molecules, part of the comple‐
ment factors enhance “inflammation” and “phagocytosis,” producing lysis of cells and 
 microorganisms. The sequential activation through the generation of complex enzymes 
from  inactive zymogens produces a cascade in which a capable enzyme generates a large 
number of active downstream molecules. Very strict regulation of downstream activation 
processes can be expected to restrict such activation to the foci where it started, thereby 
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preventing possible tissue damage [15, 16]. This set of molecules, those involved in the acti‐
vation and the regulators (distinguishing between “triggers”—those able to bypass con‐
trol systems—and “nontriggers”), is called the “complement system.” The need for both 
“amplification” and “regulation” with strict control gives an idea of the complexity of the 
“Complement System.”
5. Description of the complement system:
5.1. Alternative pathway of the “complement system”
We begin with the description of this pathway, which although referred to as “alternative” 
is phylogenetically older than the “classical pathway.” It does not require the presence of 
 antibodies (Abs) for activation, thus constituting an important defense in the early stages of 
infection, when there are no significant amounts of Ab synthesized. Continuously “at rest,” 
it operates at a low level, and it is amplified in the presence of certain factors. So we can 
 differentiate as follows:
(a) Alternative pathway “resting,” “idle,” or “pacemaker”
(1) In normal plasma conditions (absence of infection), the internal thioester bond of the C3 
fraction is spontaneously hydrolyzed in a low ratio with a water molecule (H
2
O) forming 
the complex C3(H
2
O), also referred to as “C3i” (“tick‐over” or “idle” activation) (Figure 3).
(2) C3(H
2
O) or “C3i”: It binds to factor B, forming the C3(H
2
O)B complex, also referred to 
as “C3iB.” Factor B is equivalent to the C2 factor of the classical pathway detailed later.
(3) The D factor acting on the C3(H
2
O)B complex, breaking fraction B and generating 
 subproducts B1 and C3iBb.
(4) The C3iBb complex acts as a “C3 convertase” in fluid phase cleaving C3 into C3a and 
C3b*.
(5) The “C3b*” in fluid phase is hydrolyzed by water inactivating it. However, if by some 
chance the “C3b*” bonds covalently to an external surface (“recognition of the strange”), 
the “amplification of the alternative pathway” would occur. It is said that “C3b *”does not 
start this amplification within the body due to regulatory proteins that prevent it, such as 
the following:
a. Factor H binds to C3b*, attaching to the cytoplasmic membranes.
b. Factor I breaks the C3, displacing Factor H that returns intact to serum (would be ready 
to start its action again).
c. Factor I inactivates the free C3b bound to the cytoplasmic membrane itself (iC3b).
d. Factor I cleaves iC3b into C3c (small fragment in solution) and C3dg (inactive larger 
fragment bound to membrane).
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(b) “Amplification” of the alternative pathway (“positive feedback loop”)
(1) The “C3b*” binds covalently to an external surface (“recognition of the strange”) that 
amplifies in such a way that many C3b molecules anchor (Figure 3).
(2) The membrane‐bound C3b binds to Factor B, forming the C3bB complex.
(3) Factor D (with serine protease activity) acts on C3bB, breaking the bound “B,” releasing 
Ba and forming the active C3bBb complex.
(4) The C3bBb complex (with C3 convertase activity in Bb) is quickly dissociated, unless it 
is stabilized by binding to the host Factor P (also called “properdin”), forming the stable 
complex C3bBbP (the C3 convertase bound to alternative pathway membrane).
(5) The C3bBb complex produces rupture of numerous C3 molecules, whose C3b fragments 
bind near the same membrane‐bound convertase.
(6) Such “feedback loop” is also activated by the C4b2a complex (C3 convertase) of the 
 classical complement pathway.
5.2. Classical pathway of the “complement system”
1. Activation of the complement system via the classical pathway requires the formation 
of the antigen‐antibody complex (Ag‐Ab), being the Ab of the subisotypes IgM, IgG1, 
IgG2, or IgG3. This interaction gives rise to conformational changes in the Fc fragment of 
 immunoglobulin (Ig) generating an attachment site for the C1 fraction in the Cγ2 domain 
(constant part “2” of the IgG heavy chain) or the Cμ3 domain (constant part “3” of the IgM 
heavy chain).
Figure 3. Alternative pathway activation of the complement system.
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2. The C1 fraction of the complement system is composed of five subunits: a “C1q” subunit 
(stem with six helical arms, three copies of a fundamental unit in a “Y,” which in turn 
consists of two groups of three chains each together form a triple helix), two C1r subunits 
(arranged resting on the two arms of C1q), and two C1s subunits (arranged resting on the 
two arms of C1q, whose catalytic domains are arranged toward the center), stabilized by 
the Ca++ cation.
3. The C1q fraction is capable of binding to the Fc region of immunoglobulins provided they 
form part of immunocomplexes, such that
a. It can bind to two or more IgG molecules through the Cγ2 domain when bound to the 
same Ag molecule (several IgG molecules are part of the same immunocomplex). IgG 
has only one binding site per molecule, so at least two IgG molecules are necessary to 
activate the complement system.
b. It can bind to two or more Cμ3 domains of different pentametric IgM subunits. The 
free pentametric IgM is “flat” but on binding to Ag, the Fab arms adopt angles with 
the Fc portions (in the “staple” configuration), and then C1q can bind to different 
 monomers of the same pentametric IgM. The IgM exposes more adhesion sites when 
it is in “staple” configuration, explaining why the IgM is more likely to activate the 
complement system.
4. Binding of multiple domains of the same C1 complex induces a conformational change 
that activates a “C1r” molecule by autocatalysis, which in turn activates the other “C1r” 
molecule. Once activated, the two “C1r” molecules exert hydrolysis of both C1s molecules 
to be activated, which is when they possess serine esterase activity.
5. The binding of several globular domains of the same C1 complex appears to induce a con‐
formational change in this, which involves the activation of a C1r molecule by autocataly‐
sis; in turn, this activated C1r activates the other C1r molecule. The two active molecules 
exert C1r hydrolysis of the two C1s, whereby they are activated: the two active C1s possess 
serine esterase activity (Figure 4).
6. C1s has two substrates: C2 and C4. Note at this point the regulatory role of the C1 inhibi‐
tor (C1‐INH) molecule. A deficiency in this would result in uncontrolled activation of C1s 
acting on C2 and C4, with the consequent decrease in the levels of these two complement 
fractions that is apparent in patients with C1‐INH‐HAE:
a. C1s bind to C4, producing two fragments: C4a (small fragment that diffuses into the 
plasma) and C4b (large fragment that binds to the membrane of the “target cell”). The 
C4a fraction is an “anaphylotoxin” that has importance later in this chain.
b. C1 finds a binding site on C4b, and like everything around C1s is cleaved into two 
fragments: C2a (large fragment attached to C4b) and C2b (small fragment that diffuses 
into the plasma).
7. The C4bC2a complex (formed by the C2a and C4b bond) is called “C3 convertase” since it 
activates C3 in fragments C3a and C3b (Figure 5):
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a. The intact C3 fraction has a very stable internal thioester bond between a cysteine and 
a glutamine (product of posttranslational modification) whose half‐life is close to 600 h.
b. The C4bC2a complex catalyzes the proteolytic cleavage of C3 near the amino terminus 
of the α chain, with generation of the C3a and C3b fraction*.
c. The unstable C3b* component has the very unstable thioester bond, whose half‐life is 
only 60 μs because it is susceptible to nucleophilic attack (this is due to the negative 
charge of sulfur (—S), while carbon remains as carbonyl group (—C+=O)).
d. A nearby nucleophilic group belonging to protein or cell surface carbohydrate reacts 
with the electrophilic C3b* carbonyl group, resulting in covalent bond (by —CO—O—) 
between the C3b and the cell surface.
e. The C3a fraction is an “anaphylotoxin” that will be important later in this chain.
f. Note that it is able to generate “tens” of C3b fragments, which is why this step is con‐
sidered an “amplifier.” However, not all “C3b” generated participate in the comple‐
ment pathway since a portion diffuses into the plasma functioning as an “opsonizing 
agent.”
8. The C3b fraction binds to C4bC2a, forming the C4b2aC3b complex, called “C5 convertase,” 
as the portion of the C3b fraction of this complex binds to C5, hydrolyzing it into C5a and 
C5b. The C5a fraction is an “anaphylotoxin” that will be important later in this chain. 
The C5b fraction is a key element for the formation of the membrane “attack complex” 
 (Figure 3). This step is already part of the “final common lytic pathway” between the 
“ classical pathway” and “lectin pathway.”
Figure 4. Classical pathway activation of the complement system, showing the binding of the C1q subunit to the Ig Fc, 
which is bound in turn to the cell membrane.
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5.3. Lectin pathway of the “complement system”
The lectin pathway is a third way of complement system pathway activation different from 
the classical activation of C2 and C4 fractions (Figure 6). It starts with the action of the “man‐
nan‐binding protein” (MBP), which is structurally very similar to the C1q fraction (hexamers 
with 18 identical polypeptide chains coiled in groups of 3) and can bind two C1r subunits 
and two C1s subunits. However, it brings its own serine protease (called MASP) with 40% 
homology to C1r or C1s. MBP binds preferentially to the ends of mannose, fucose, and glu‐
cosamine of glycoproteins or polysaccharides present in the bacterial membrane. In a similar 
manner as described in the “classical pathway” with C1q2r2s complex, when MBP binds to 
carbohydrates it undergoes a conformational change, which in turn activates the serine pro‐
tease (MASP). Activated MASP acts sequentially on C2 and C4 fractions to produce the “C3 
convertase of the classical pathway.”
MASP‐1 has been recently shown to cleave bradykinin from HMWK [17] and its levels, 
together with the complex MASP1‐C1‐INH, have been related to disease severity in C1‐INH‐
HAE [18].
5.4. Common final pathway of the “complement system”
The three activation pathways of the complement system (the classical pathway, the alterna‐
tive pathway, and the lectin pathway) converge in a common final lytic pathway. The C5b, 
C6, C7, C8, and C9 fractions participate in the final lytic complement pathway and form a 
molecular structure known as “membrane attack complex” (MAC) (Figure 7).
Figure 5. Classical pathway for the activation of the complement system, where the formation of the C1qrs complex until 
the formation of the C3b molecule can be observed.
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Figure 6. Lectin pathway for the activation of the complement system.
Figure 7. Major events in the lytic pathway cell membrane leading to the C9 polymerization and pore formation in the 
cell membrane.
Pathophysiology of Bradykinin-Mediated Angioedema: The Role of the Complement System
http://dx.doi.org/10.5772/67704
161
MAC insertion into the cytoplasmic membrane causes an intercellular‐extracellular commu‐
nication pore with consequent ion exchange leading to cell death. The sequential steps are as 
follows:
1. As already mentioned, the final stage of the three activation pathways is common and consists 
in the formation of the “C5 convertase” that breaks the C5 fraction and triggers the appear‐
ance of the “membrane attack complex” (MAC). The steps at every pathway are as follows:
a. The “classical pathway”: the C4b2aC3b complex catalyzes the cleavage of C5 into C5a 
and C5b.
b. The “lectin pathway”: the C4b2aC3b complex catalyzes the cleavage of C5 into C5a 
and C5b.
c. The “alternative pathway”: a covalent attachment of a “new” C3b that forms part of the 
“C3 convertase,” forming the C3bBb3b complex.
2. C5b binds to the cytoplasmic membrane hydrophilic region.
3. C5b binds to C6, forming the C5bC6 complex.
4. C5bC6 binds to C7, forming C5bC6‐7 complex, which has already hydrophobic regions 
that are capable of penetrating into the inner section of the lipid bilayer.
5. C5bC6‐7 binds to C8, forming C5bC6‐7‐8 complex, which is capable of forming a 10 
 Armstrong pore capable of destroying erythrocytes but not able to destroy nucleated cells.
6. C5bC6‐7‐8 binds to about 14 C9 units to form the C5b‐C6‐7‐8‐poli9 complex (or MAC), 
which is capable of forming a 70–100 Armstrong pore by contacting the intracellular with 
the extracellular medium with the subsequent ion and water exchange, leading to cell 
death.
6. Complement disorders
Complement disorders have been traditionally linked to immunodeficiency and associated 
with severe or frequent infections. More recently, complement has been recognized for its role 
in inflammation, autoimmune disorders, and vision loss [19]. The identification of hereditary 
and acquired complement deficiencies in humans has led to a better understanding of the bio‐
logic importance of the complement system in immunity and autoimmune disease (Table 2).
Complement protein Gene (chromosome) Effects of deficiency (commonly associated infections)
C1q 1p36.12 (A, B, and C chains) Immune‐complex disease
Meningitis, pneumonia, sepsis (Streptococcus 
pneumoniae, Neisseria meningitidis)
C1r 12p13.31 Meningitis, pneumonia, sepsis (encapsulated 
bacteria)
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Complement protein Gene (chromosome) Effects of deficiency (commonly associated infections)
C1s 12p13.31 Meningitis, pneumonia, sepsis (encapsulated 
bacteria)
C1‐INH 11q11‐q13.1 C1‐INH‐HAE
C2 6p21.33 Immune‐complex disease
Meningitis, osteomyelitis, pneumonia, sepsis 
(Staphylococcus aureus, Streptococcus pneumoniae, 
Neisseria meningitidis)
C3 19p13.3 Respiratory tract infections (Haemophilus influenzae, 
Streptococcus pneumoniae, Streptococcus pyogenes, 
Neisseria meningitidis)
C4 6p21.33 (Rodgers blood group 
and Chido blood group)
Immune‐complex disease
Meningitis, pneumonia, sepsis (encapsulated 
bacteria)
C5 9q33.2 SLE‐like symptoms
Meningitis, sepsis (Neisseria meningitidis)
C6 5p13.1 SLE‐like symptoms
MPGN
Meningitis, sepsis (Neisseria meningitidis)
C7 5p13.1 Scleroderma, rheumatoid arthritis, and an SLE‐like 
syndrome
Meningitis, sepsis (Neisseria meningitidis)
C8 1p32.2 (alpha chain)
1p32.2 (beta chain)
9q34.3 (gamma chain)
Meningitis, sepsis (Neisseria meningitidis)
C9 5p13.1 Meningitis, sepsis (Neisseria meningitidis)
Factor D 19p13.3 Meningitis (Neisseria meningitidis)
Factor H 1q31.3 Recurrent pyogenic infections (Haemophilus influenzae, 
Streptococcus pneumoniae, Neisseria meningitidis)
Factor I 4q25 Recurrent pyogenic infections (Haemophilus influenzae, 
Streptococcus pneumoniae, Neisseria meningitidis)
Factor P (properdin) Xp11.23 Meningitis (Neisseria meningitidis)
MBL (or MBP) 10q11.2‐q21 Respiratory tract infections
MASP2 1p36.22 Respiratory tract infections
CD59 (or MAC‐IP, MAC‐IP, 
protectin)
11p13 Autoimmune‐like conditions including paroxysmal 
nocturnal hemoglobinuria
DAF (or CD55) 1q32.2 Autoimmune‐like conditions including paroxysmal 
nocturnal hemoglobinuria
C1‐INH‐HAE = hereditary angioedema with C1 inhibitor deficiency; CD59 = cluster of differentiation 59; MAC‐
inhibitory protein (MAC‐IP), membrane inhibitor of reactive lysis (MIRL) or protectin; DAF = complement decay‐
accelerating factor; MASP2 = manna‐binding lectin serine protease 2 (also called mannan‐binding protein‐associated 
serine protease 2); MBL = mannose‐binding lectin (also called mannose‐binding protein or mannan‐binding protein 
(MBP); MPGN = membranoproliferative glomerulonephropathy; SLE = systemic lupus erythematous.
Table 2. Clinical significance of complement deficiencies [20–24].
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7. Classification of angioedema due to functionally active C1 esterase 
inhibitor protein (C1 inhibitor) deficiency
Functionally active C1‐INH deficiency can be hereditary or acquired. The hereditary form is 
a primary immunodeficiency [25] and is the most common genetic defect of the complement 
system [26]. The absence or malfunction of C1‐INH results in the presence of attacks of AE 
(subcutaneous or mucosal swelling) due to uncontrolled activation of the contact system, with 
the generation of bradykinin, a vasoactive peptide released from HMWK [9].
7.1. Hereditary angioedema
C1‐INH‐HAE is a genetic autosomal dominant disease characterized by a deficiency of the 
functionally active C1 esterase inhibitor (C1 inhibitor) protein. Initially, it was believed that 
it affected one individual per 10,000–150,000 people, but being a rare disease it makes an 
 estimate of prevalence difficult to pinpoint [27]. It could affect around 2000–3000 people in the 
USA [28]. There is a register of patients in Spain where the minimum prevalence is 1.09 per 
100,000 inhabitants [29], while another register in Denmark describes a prevalence rate of 
1.41 per 100,000 inhabitants [30]. The highest published prevalence is in Norway with 1.75 per 
100,000 inhabitants [31]. Delays in diagnosis (an average of 13.1 years in the Spanish study) 
[29] along with the possibility of misdiagnosis and lack of recognition of the disease may 
mean that the true prevalence may be higher than estimates suggest. To date, no studies have 
shown differences in prevalence between ethnic groups.
Two phenotypic variants were described [32, 33]. Type I (HAE‐I) is the most common (85%), 
characterized by a quantitative decrease of C1‐INH, which results in a decrease in functional 
activity; type II (HAE‐II) (15%) is characterized by normal or elevated levels of dysfunctional 
C1‐INH. In both cases, the defect is transmitted as an autosomal dominant form, although 
with different genetic alterations. There is another estrogen‐dependent hereditary AE  variant 
in which both levels and function of C1‐INH are normal and which has been called HAE 
type III [34, 35].
7.2. Acquired angioedema
C1‐INH‐AAE is biochemically characterized by low C1‐INH concentrations and/or functions 
and no evidence of heredity. It is mainly associated with B cell lymphoproliferative  disorders 
and occasionally with autoimmune, neoplastic, or infectious diseases [14]. Initially, it was 
 classified into two types: type I, with most patients having an associated B cell line malignancy; 
type II, there were anti‐C1‐INH autoantibodies that interfered with C1‐INH functional  activity 
[36]. C1‐INH production is normal or slightly increased. In many patients with type I, the 
paraproteinemia or M component actually behaves as an anti‐C1‐INH autoantibody, so some 
authors such as Cicardi suggest that the distinction between types I and II may be artificial [37].
Acquired C1‐INH deficiency is characterized by the activation of the classical complement 
pathway and accelerated catabolism of C1‐INH and the activation of the contact system [9]. 
This results in low C4 and C2 levels and normal C3 levels in plasma. C1q levels are frequently 
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very low in C1‐INH‐AAE and this feature is frequently used to differentiate the acquired from 
the hereditary form of C1‐INH deficiency [14].
8. Bradykinin as common final mediator of “bradykininergic” 
angioedema
8.1. Formation of bradykinin
BK is a linear nonapeptide (with sequence Arg1‐Pro2‐Pro3‐Gly4‐Phe5‐Ser6‐Pro7‐Phe8‐Arg9) 
produced endogenously in humans and other mammals as a result of the proteolytic activity 
of kallikrein on kininogens [38, 39].
Kallikreins belong to serine proteases and fall into two groups: tissue and plasma kallikreins. 
Within the tissue kallikreins, a family of 15 proteins is true kallikrein (hk1) and prostate‐
specific antigen (PSA or hk3) [39–41]. Plasma kallikrein is involved in processes that initiate 
coagulation especially during the activation phase due to contact with negatively charged 
surfaces. The plasma and tissue kallikreins release vasoactive peptides known as kinins 
implicated in biological processes such as the relaxation of vascular smooth muscle (hypoten‐
sion), increased vascular permeability, smooth muscle contraction of the bronchial tree, and 
pain [39–41]. This peptide family produces BK release due to plasma kallikrein action on the 
HMWK, while it also releases Lys‐bradykinin (Lys‐BK) by the action of tissue kallikrein hk1 
on low‐molecular‐weight kininogen (LMWK) [39–41] (Figure 8).
8.2. Other forms of angioedema with activation of the contact system
HAE type III, described in 2000 by two independent research groups [35, 42], has been also 
named as hereditary angioedema with normal C1‐INH (nC1‐INH‐HAE) [7]. A subgroup of 
patients with nC1‐INH‐HAE (approximately 30%) has a mutation in exon 9 of F12 gene [7] 
and this type of AE is known as FXII‐HAE [7]. The rest have not known mutation and are 
known as unknown‐HAE (U‐HAE) [7].
FXII is a protease involved in the activation of the coagulation and contact systems and these 
mutations found in F12 gene in patients with FXII‐HAE have been shown to produce hyperac‐
tivability of coagulation factor FXII, with the consequent activation of the contact system [43].
8.3. Inhibition of bradykinin‐metabolizing enzymes
Once produced, kinins are rapidly metabolized by metallopeptidases: neutral endopepti‐
dase (NEP), angiotensin‐converting enzyme (ACE), dipeptidyl peptidase‐IV (DPP‐IV), ami‐
nopeptidase P (APP), carboxypeptidases (CPN, CPM), and endothelin‐converting enzyme‐1 
(ECE‐1). Dendorfer et al. [44] described the metabolic pathways of BK degradation in murine 
models. In human plasma, BK is cleaved on the Pro7‐Phe8 and Phe8‐Arg9 bonds by the action 
of the two largest kininases: ACE and CPN [45]. Besides, in the 1960s it was reported that 
carboxypeptidase A cleaved the Pro7‐Phe8 bond [46], while carboxypeptidase B cleaved the 
Pathophysiology of Bradykinin-Mediated Angioedema: The Role of the Complement System
http://dx.doi.org/10.5772/67704
165
Phe8‐Arg9 bond [46]. Generally, carboxypeptidases remove Arg9 (carboxyl terminus) from 
the kinin molecule. Although NEP plays an important role in the kidney and epithelium, 
unlike ACE it barely exerts its action in plasma. APP cleaves BK in the Arg1‐Pro2 bond [47]. 
NEP and ACE cleave BK at the Pro7‐Phe8 bond (releasing the dipeptide Phe8‐Arg9) [48]; NEP 
further cleaves the Gly4‐Phe5 bond and ACE in the Phe5‐Ser6 bond [48].
The following drug classes can cause acute AE by inhibition of the BK‐metabolizing pathway 
(Figure 8):
• ACE (EC 3.4.15.1) inhibitors: lisinopril, captopril, enalapril, and ramipril.
• DPP‐IV (EC 3.4.14.5) inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and 
linagliptin.
• APP (EC 3.4.11.9) inhibitors: apstatin [49].
• CPN and CPM inhibitors.
• NEP, also known as neprilysin (EC 3.4.24.11) inhibitor: SQ29072 [50], SCH39370 [51], 
 candoxatrilat [52], phosphoramidon [53], BP102 [54], and ecadotril [55].
• ECE‐1 (EC 3.4.24.71) inhibitor: CGS35066 [56].
• Dual inhibitor of NEP and ACE: omapatrilat [57], fasidotril [58], sampatrilat [59], and 
 mixanpril [60].
• Dual inhibitor of NEP and ECE‐1: SLV‐306 [61], S‐17162 [62], CGS 26303 [63, 64], CGS 26393 
[65], CGS 31447 [66], WS 75624B [67], B‐90063 [68], CGS 34226 [69], and CGS 34043 [70].
• Triple inhibitor of ECE‐1, NEP, and ACE: CGS 35601 [71–73] and CGS 37808 [74].
Figure 8. Formation of kinins in plasma and tissues. Each kinin is formed from kininogen by the action of a different 
enzyme.
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8.4. Bradykinin receptor ligands
The biological effects of kinins involve the activation of specific receptors on the  surface 
of the target cell. At least two different kinin receptors are known [75, 76]: BK  receptor 
B1 ( bradykinin receptor B1, also known as BDKRB1, B1R, BKR1, B1BKR, BKB1R, and 
BRADYB1) [77], which is coded in region 14q32.1‐q32.2, and BK receptor B2 (bradykinin 
receptor B2, also known as BDKRB2, B2R, BK2, BK‐2, BKR2, and BRB2) [78], which is coded 
in region 14q32.1‐q32.2.
BKR1 binds and is activated by des‐[Arg9]‐bradykinin (DBK) and des‐[Arg9]‐Lys‐bradykinin 
(Lys‐BK), formed by the action of carboxypeptidases on Lys‐BK and BK, respectively [79].
BKR1 is expressed in low amounts on normal physiological conditions in smooth muscle of 
blood vessels being regulated additively by inflammation [75, 79]. During stressful situations 
(trauma, tissue pressure, or inflammation with increase of IL1β or TNFα) [80, 81], the effects 
on BKR1 can predominate.
On the contrary, BKR2 binds selectively with BK and kallidin, mediating most of the effects of 
the contact system activation in the absence of inflammation.
Antagonists have been developed for both types of receptors, such as des‐[Arg9]‐bradykinin‐
Leu8 for BKR1 and HOE140 (icatibant acetate) for BKR2 [82]. Icatibant acetate has been shown 
to be effective for the treatment of acute AE attacks in C1‐INH‐HAE [7, 8, 83].
In summary, most of the biological effects of kinins are mediated by BKR2 and under 
 conditions of inflammation or tissue damage there is induction of BKR1 [84] (Figure 9).
Figure 9. Bradykinin receptor ligands.
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Both receptors belong to the superfamily of receptors that have seven transmembrane domains 
coupled to G proteins, differing both in primary structure, expression, and  regulation of their 
tissue distribution [85, 86].
Two types of G protein‐coupled receptors have been found that bind to BK mediating its 
response in pathophysiological conditions. To summarize, there are stimulatory G proteins 
(Gs and Gq) and inhibitory G proteins (Gi). Gs binds to GTP and activates adenylate cyclase, 
increasing the amount of intracellular cAMP. Gi binds to GTP and inactivates adenylate 
cyclase, indirectly reducing the amount of intracellular cAMP. Gq binds to GTP and activates 
PLC, increasing the amount of DAG, IP, and intracellular Ca++. Transduction pathways stimu‐
lated by kinins have been extensively investigated in endothelial cells, where BKR1 interacts 
with Gq and Gi proteins, using the same signaling pathways as BKR2 (Figure 10).
BKR2 binds to G proteins and activates phospholipases A
2
 and C. The kinin‐induced increase 
in phospholipase C (PLC) causes it to act on their specific substrate, phosphatidylinositol 
biphosphate (PIP2), hydrolyzing it generating the two metabolites: inositol triphosphate (IP
3
) 
and diacylglycerol (DAG). IP3 binds to a specific receptor (IP3R) in the endoplasmic reticu‐
lum facilitating the release of intracellular Ca++. IP3, possibly together with its metabolite, IP4, 
can regulate calcium channels of the plasma membrane allowing the entry of extracellular 
calcium into the cell [87, 88]. The other metabolite of PIP2 hydrolysis, DAG, is responsible for 
the activation of protein kinase C (PKC) [89, 90]. PKC consists of one polypeptide chain with 
two functional domains: (a) a hydrophobic domain for binding to the cell membrane and 
(b) a hydrophilic domain, which possesses catalytic function. PKC at cellular rest is found 
in an inactive form in the cytosol, but once stimulated by DAG together with Ca++ ions it 
 translocates to the cell membrane to exert its function of protein kinase in serine and  threonine 
Figure 10. Bradykinin receptors and G‐protein–coupled receptor‐signaling pathway.
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amino acids. BK has been shown to activate a Ca++‐dependent PKC and PKC not dependent 
on this ion, as well as atypical isoforms [91]. The stimulation of phospholipase A
2
 (PLA
2
) 
releases arachidonic acid from membrane phospholipids [92], which can be  metabolized in 
the form of powerful inflammatory mediators.
In addition, BKR2 transitorily promotes phosphorylation of tyrosine from tyrosine kinases 
such as MAP kinase (“mitogen‐activated protein kinase”), as well as the activation of the JAK/
STAT pathway. Activated BKR2 interacts directly with nitric oxide synthase (NOS) resulting 
in nitric oxide (NO) [93].
9. Conclusions
C1‐INH‐HAE is a rare inherited disorder, characterized by recurrent AE attacks in  various 
regions of the body. C1‐INH‐AAE is an acquired disease usually due to the presence of 
 anti‐C1‐INH autoantibodies. The lack of C1‐INH leads to inappropriate activation of the 
 kallikrein‐kinin system and release of BK, a vasoactive mediator.
nC1‐INH‐HAE is another inherited form of AE, with no C1‐INH deficiency, but a  probable 
increase in BK formation due to mutation in exon 9 of F12 gene with subsequent hyper‐
activability.
BK (common final mediator of BK‐AE) is a linear nonapeptide (with sequence  Arg1‐Pro2‐
Pro3‐Gly4‐Phe5‐Ser6‐Pro7‐Phe8‐Arg9) produced endogenously in humans and other mam‐
mals as a result of the proteolytic activity of kallikrein on kininogens.
Some drugs that inhibit the catabolism of BK have been implicated in the development of AE. 
These include ACEIs, DPP‐IV inhibitors, APP inhibitors, and NEP inhibitors.
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